ICU Medical (ICUI) to Release Quarterly Earnings on Monday

ICU Medical (NASDAQ:ICUIGet Rating) is scheduled to be posting its quarterly earnings results after the market closes on Monday, August 8th. Analysts expect ICU Medical to post earnings of $1.69 per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

ICU Medical (NASDAQ:ICUIGet Rating) last issued its quarterly earnings data on Monday, May 9th. The medical instruments supplier reported $1.32 earnings per share for the quarter, missing analysts’ consensus estimates of $1.53 by ($0.21). The firm had revenue of $543.10 million for the quarter, compared to the consensus estimate of $557.33 million. ICU Medical had a return on equity of 7.89% and a net margin of 2.68%. The company’s revenue was up 70.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.34 EPS. On average, analysts expect ICU Medical to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

ICU Medical Trading Up 2.3 %

Shares of ICUI stock opened at $179.63 on Friday. The stock’s fifty day simple moving average is $170.58 and its 200 day simple moving average is $199.90. ICU Medical has a twelve month low of $158.60 and a twelve month high of $282.00. The firm has a market capitalization of $4.29 billion, a P/E ratio of 88.05 and a beta of 0.55. The company has a quick ratio of 1.29, a current ratio of 2.38 and a debt-to-equity ratio of 0.75.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. KeyCorp reduced their price target on ICU Medical from $265.00 to $230.00 and set an “overweight” rating on the stock in a research report on Wednesday. StockNews.com lowered ICU Medical from a “buy” rating to a “hold” rating in a research report on Thursday, May 12th. Finally, TheStreet lowered ICU Medical from a “b-” rating to a “c” rating in a research report on Wednesday, May 11th.

Insider Activity

In other news, Director Elisha W. Finney sold 217 shares of the business’s stock in a transaction dated Thursday, May 12th. The stock was sold at an average price of $170.53, for a total value of $37,005.01. Following the transaction, the director now directly owns 1,933 shares of the company’s stock, valued at approximately $329,634.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Elisha W. Finney sold 217 shares of the company’s stock in a transaction that occurred on Thursday, May 12th. The stock was sold at an average price of $170.53, for a total transaction of $37,005.01. Following the transaction, the director now directly owns 1,933 shares of the company’s stock, valued at approximately $329,634.49. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Virginia Ruth Sanzone sold 750 shares of the company’s stock in a transaction that occurred on Thursday, May 12th. The stock was sold at an average price of $173.56, for a total value of $130,170.00. Following the transaction, the vice president now directly owns 3,371 shares in the company, valued at $585,070.76. The disclosure for this sale can be found here. 7.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ICUI. PNC Financial Services Group Inc. increased its holdings in ICU Medical by 110.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,766 shares of the medical instruments supplier’s stock worth $615,000 after purchasing an additional 1,452 shares in the last quarter. Virtu Financial LLC bought a new stake in ICU Medical during the 1st quarter worth approximately $585,000. Quantamental Technologies LLC bought a new stake in ICU Medical during the 1st quarter worth approximately $458,000. Keeley Teton Advisors LLC bought a new stake in ICU Medical during the 1st quarter worth approximately $396,000. Finally, Guggenheim Capital LLC bought a new stake in ICU Medical during the 1st quarter worth approximately $396,000. 94.93% of the stock is owned by institutional investors and hedge funds.

About ICU Medical

(Get Rating)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs.

Featured Stories

Earnings History for ICU Medical (NASDAQ:ICUI)

Want More Great Investing Ideas?

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.